CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,246 enrolled
Drug / intervention
alphatocopherol +3 moredrug
Likely dose
alphatocopherol 400 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00040378
NCT00040378N/ACompleted
CompareCT.gov

Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

Frederick Schmitt·observational·Posted Jun 27, 2002·Updated Mar 14, 2018

In Brief

An observational study evaluating alphatocopherol, Selenium, and 2 other interventions for Alzheimer Disease. Completed, enrolled 4,246 participants across 91 sites in 3 countries.

Detailed Summary

The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesCanada, Puerto Rico, United States
CollaboratorsNational Institute on Aging (NIA), National Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2002
Enrollment StartMay 1, 2002
Primary CompletionJan 1, 2014
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11.7 yearsPosted 24.0 years ago

Interventions

alphatocopheroldrug

400 IU daily

Seleniumdrug

200mcg daily

Placebo replacement for vitamin Edrug

1 placebo pill daily

Placebo replacement for Seleniumdrug

1 placebo pill daily